115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66747)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3743)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • 5-year follow-up of the phase 2 optic study in patients with chronic-phase chronic myeloid leukemia: Efficacy, safety, and first end-of-treatment mutational results
    Meeting Abstract

    Cortes, J. E.; Deininger, M. W.; Apperley, J.; Arthur, C. K.; Chuah, C.; Hochhaus, A.; de Lavallade, H.; Lipton, J. H.; Lomaia, E.; McCloskey, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma: Final results from the phase 2 PRIMO trial
    Meeting Abstract

    Mehta-Shah, N.; Zinzani, P. L.; Jacobsen, E. D.; Zain, J.; Mead, M.; Casulo, C.; Gritti, G.; Pinter-Brown, L. C.; Izutsu, K.; Bentur, O. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Patients with AML and an IDH2-R172 mutation exhibit a unique response to intensive induction chemotherapy, suggesting futility of mid-cycle bone marrow biopsy and caution when considering re-induction
    Meeting Abstract

    Yisraeli Salman, M.; Terry, A. R.; Derkach, A.; Nemirovsky, D.; Chin, K. K.; Valtis, Y. K.; Boussi, L.; Spivey, T.; Xiao, W.; Famulare, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Pembrolizumab for front-line treatment of extranodal NK/T-cell lymphoma
    Meeting Abstract

    Moskowitz, A.; Advani, R. H.; Ganesan, N.; Chang, T.; Hancock, H.; Davey, T.; Miller, T.; Gibaldi, A.; Smith, M.; Assini, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Final response and survival results from a phase II trial of pembrolizumab and entinostat in relapsed/refractory Hodgkin lymphoma
    Meeting Abstract

    Stuver, R.; Vardhana, S. A.; Ganesan, N.; Boardman, A. P.; Caron, P.; Chang, T.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Codon-specific differences in RAS mutations in AML and differential response to therapeutic agents
    Meeting Abstract

    Anandappa, A. J.; Trivedi, V.; Merlinsky, T.; Delgaudio, N.; Guzzardi, E.; Wooten, A.; Starczynowski, D.; Bowman, R. L.; Levine, R.; Miles, L. A.
    Blood (2024)

    Fulltext@MSK | Save
  • Efficacy of a novel BCL-XL degrader, DT2216, in preclinical models of post-myeloproliferative neoplasm secondary AML
    Meeting Abstract

    Wang, Z.; Skwarska, A.; Poigailwar, G.; Chaudhry, S.; Rodriguez-Meira, A.; Sui, P.; Olivier, E.; Jia, Y.; Ramage, C. L.; Zheng, G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Role of B cell recovery in relapse risk and CD19 phenotype following real-world use of tisagenlecleucel for pediatric B-acute lymphoblastic leukemia: A multi-institutional retrospective study
    Meeting Abstract

    Zeng, X. L.; Kwon, S.; Vatsayan, A.; Baggott, C.; Prabhu, S.; John, S.; Pacenta, H. L.; Phillips, C. L.; Rossoff, J.; Talano, J. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Feasibility and implementation of the ASH Research Collaborative's COVID-19 OutcomeS in Myeloma and the Impact of VaCcines (COSMIC): A decentralized, real-world evidence study for patients with multiple myeloma to monitor outcomes related to COVID-19 vaccines and infections
    Meeting Abstract

    Wood, W. A.; Semmel, E. A.; James, S.; Neuberg, D. S.; Hewitt, K.; Anderson, K. C.; Kumar, S.; Schroeder, M. A.; Chung, D. J.; Rosenberg, A. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • The LMO2-LDB1-TAL1 complex regulates transcription networks in AML relapse
    Meeting Abstract

    Dunham, N.; Wang, Z.; Neelamraju, Y.; Guo, Y.; Hardwick, J.; Maier, B.; Meydan, C.; Gandara, J. A.; Lee, T.; Prajapati, S.; more...
    Blood (2024)

    Fulltext@MSK | Save